Based on the results of our preclinical investigation, we further analyzed whether clinical correlations occur between the expression levels of resistin, CXCL5, and ERK phosphorylation in breast cancer patients by immunohistochemistry (Fig. 6A). This evidence concerns the gene CXCL5 and breast cancer.